147 related articles for article (PubMed ID: 31945344)
1. A Small Molecule CCR2 Antagonist Depletes Tumor Macrophages and Synergizes with Anti-PD-1 in a Murine Model of Cutaneous T-Cell Lymphoma (CTCL).
Wu X; Singh R; Hsu DK; Zhou Y; Yu S; Han D; Shi Z; Huynh M; Campbell JJ; Hwang ST
J Invest Dermatol; 2020 Jul; 140(7):1390-1400.e4. PubMed ID: 31945344
[TBL] [Abstract][Full Text] [Related]
2. Targeting both tumour-associated CXCR2
Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC
Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437
[TBL] [Abstract][Full Text] [Related]
3. Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation.
Kaplanov I; Carmi Y; Kornetsky R; Shemesh A; Shurin GV; Shurin MR; Dinarello CA; Voronov E; Apte RN
Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1361-1369. PubMed ID: 30545915
[TBL] [Abstract][Full Text] [Related]
4. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
Yang H; Zhang Q; Xu M; Wang L; Chen X; Feng Y; Li Y; Zhang X; Cui W; Jia X
Mol Cancer; 2020 Feb; 19(1):41. PubMed ID: 32103760
[TBL] [Abstract][Full Text] [Related]
5. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
6. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
7. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment.
Kuo IY; Yang YE; Yang PS; Tsai YJ; Tzeng HT; Cheng HC; Kuo WT; Su WC; Chang CP; Wang YC
Theranostics; 2021; 11(14):7029-7044. PubMed ID: 34093869
[No Abstract] [Full Text] [Related]
8. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
Li X; Yao W; Yuan Y; Chen P; Li B; Li J; Chu R; Song H; Xie D; Jiang X; Wang H
Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
[TBL] [Abstract][Full Text] [Related]
9. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
10. Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.
Han Z; Wu X; Qin H; Yuan YC; Schmolze D; Su C; Zain J; Moyal L; Hodak E; Sanchez JF; Lee PP; Feng M; Rosen ST; Querfeld C
JCI Insight; 2023 Jul; 8(13):. PubMed ID: 37427589
[TBL] [Abstract][Full Text] [Related]
11. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
12. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
13. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.
Dai X; Lu L; Deng S; Meng J; Wan C; Huang J; Sun Y; Hu Y; Wu B; Wu G; Lovell JF; Jin H; Yang K
Theranostics; 2020; 10(20):9332-9347. PubMed ID: 32802195
[No Abstract] [Full Text] [Related]
14. Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
Ma P; Liu J; Qin J; Lai L; Heo GS; Luehmann H; Sultan D; Bredemeyer A; Bajapa G; Feng G; Jimenez J; He R; Parks A; Amrute J; Villanueva A; Liu Y; Lin CY; Mack M; Amancherla K; Moslehi J; Lavine KJ
Circulation; 2024 Jan; 149(1):48-66. PubMed ID: 37746718
[TBL] [Abstract][Full Text] [Related]
15. Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
Fei L; Ren X; Yu H; Zhan Y
Front Immunol; 2021; 12():771210. PubMed ID: 34804061
[TBL] [Abstract][Full Text] [Related]
16. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with bevacizumab and a CCR2 inhibitor for human ovarian cancer: An in vivo validation study.
Zhai T; Mitamura T; Wang L; Kubota SI; Murakami M; Tanaka S; Watari H
Cancer Med; 2023 Apr; 12(8):9697-9708. PubMed ID: 36810973
[TBL] [Abstract][Full Text] [Related]
18. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
19. Gas6 Promotes Inflammatory (CCR2
Laurance S; Bertin FR; Ebrahimian T; Kassim Y; Rys RN; Lehoux S; Lemarié CA; Blostein MD
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1315-1322. PubMed ID: 28450294
[TBL] [Abstract][Full Text] [Related]
20. IL-10 is overexpressed in human cutaneous T-cell lymphoma and is required for maximal tumor growth in a mouse model.
Wu X; Hsu DK; Wang KH; Huang Y; Mendoza L; Zhou Y; Hwang ST
Leuk Lymphoma; 2019 May; 60(5):1244-1252. PubMed ID: 30277131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
